8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 1, 2026·SEC
Olema Pharmaceuticals, Inc.(OLMA)Earnings, Financials & Key Ratios
OLMA•NASDAQ
$12.63
Price updated Jul 7, 2026
AboutOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Show more
- Revenue$0
- EBITDA-$178M-25.6%
- Net Income-$162M-25.5%
- EPS (Diluted)-1.87+15.0%
- ROE-36.61%+6.3%
OLMA Price & Volume
Olema Pharmaceuticals, Inc. (OLMA) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Clinical Burn Threatens Capital Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
Key Thesis Takeaways
- Olema Pharmaceuticals remains in a high-risk, pre-revenue development phase, with its valuation entirely dependent on the successful clinical progression of the OP-1250 candidate.
- The company faces significant financial pressure as R&D expenditures have escalated to $49.2 million in 2026Q1, necessitating a reliance on external financing that risks substantial shareholder dilution.
- Investors should monitor the company's ability to manage its dwindling cash reserves, which have compressed to $52.5 million, against the backdrop of intensifying clinical trial obligations.
Verdict Logic
the company's current cash position of $52.5 million against a quarterly free cash flow burn of $46.0 million suggests an imminent need for dilutive capital raises to sustain operations.
OLMA Growth Metrics
Olema Pharmaceuticals, Inc. (OLMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-43.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.93%
Return on Capital
10 Years-93.82%
5 Years-39.21%
3 Years-43.04%
Last Year-40.12%
OLMA Recent Earnings
Olema Pharmaceuticals, Inc. (OLMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.52+0.0%
$0.52
Rev
—
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.50+2.0%
$0.51
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.49-11.4%
$0.44
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.51-18.6%
$0.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.52vs $0.52+0.0% | — |
| Q2 2026 | Mar 16, 2026 | $0.50vs $0.51+2.0% | — |
| Q4 2025 | Nov 10, 2025 | $0.49vs $0.44-11.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.51vs $0.43-18.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Olema Pharmaceuticals, Inc. (OLMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.63 | $1.1B | -6.75 | — | — | -36.61% | — | |
| $56.56 | $6.78B | -17.19 | — | — | -163.52% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — |
Compare OLMA vs Peers
Olema Pharmaceuticals, Inc. (OLMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OLMA SEC Filings & Documents
Olema Pharmaceuticals, Inc. (OLMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OLMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OLMA Frequently Asked Questions
Olema Pharmaceuticals, Inc. (OLMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is OLMA profitable?
Olema Pharmaceuticals, Inc. (OLMA) reported a net loss of $185.2M for fiscal year 2025.
Dividend & Returns
What is OLMA's return on equity?
Olema Pharmaceuticals, Inc. (OLMA) has a return on equity (ROE) of -36.6%. Negative ROE indicates the company is unprofitable.
What is Olema Pharmaceuticals, Inc.'s free cash flow?
Olema Pharmaceuticals, Inc. (OLMA) had negative free cash flow of $148.7M in fiscal year 2025, likely due to heavy capital investments.